SI-Bone Inc (NASDAQ:SIBN) Major Shareholder Skyline Venture Partners V. Lp Sells 400,000 Shares

SI-Bone Inc (NASDAQ:SIBN) major shareholder Skyline Venture Partners V. Lp sold 400,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $18.25, for a total value of $7,300,000.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of SIBN traded down $0.21 during mid-day trading on Wednesday, hitting $18.44. The company’s stock had a trading volume of 285,572 shares, compared to its average volume of 119,476. The company has a debt-to-equity ratio of 0.47, a current ratio of 13.06 and a quick ratio of 12.70. The business has a 50-day moving average of $19.12. The stock has a market capitalization of $452.96 million and a price-to-earnings ratio of -25.97. SI-Bone Inc has a 1-year low of $14.08 and a 1-year high of $23.03.

SI-Bone (NASDAQ:SIBN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.40) by $0.05. The business had revenue of $16.32 million during the quarter. SI-Bone had a negative return on equity of 211.17% and a negative net margin of 46.59%. Sell-side analysts anticipate that SI-Bone Inc will post -1.45 EPS for the current fiscal year.

A number of analysts have weighed in on the company. Zacks Investment Research raised SI-Bone from a “sell” rating to a “hold” rating in a research report on Saturday, July 6th. ValuEngine raised SI-Bone from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. SI-Bone currently has a consensus rating of “Buy” and an average price target of $24.75.

Several institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of SI-Bone in the 4th quarter valued at approximately $27,000. Bank of Montreal Can acquired a new stake in shares of SI-Bone in the 2nd quarter valued at approximately $28,000. Valeo Financial Advisors LLC acquired a new stake in shares of SI-Bone in the 1st quarter valued at approximately $94,000. Private Ocean LLC acquired a new stake in shares of SI-Bone in the 2nd quarter valued at approximately $131,000. Finally, Deutsche Bank AG acquired a new stake in shares of SI-Bone in the 4th quarter valued at approximately $227,000. 39.35% of the stock is owned by institutional investors and hedge funds.

About SI-Bone

SI-BONE, Inc, a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Featured Article: Profit Margin

Insider Buying and Selling by Quarter for SI-Bone (NASDAQ:SIBN)

Receive News & Ratings for SI-Bone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SI-Bone and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit